TITLE

The Art and Science of Genetic Modification: Re-Engineering Patent Law and Constitutional Orthodoxies

AUTHOR(S)
Cripps, Yvonne
PUB. DATE
January 2004
SOURCE
Indiana Journal of Global Legal Studies;Winter2004, Vol. 11 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on patent laws and constitutional orthodoxies in biotechnology. Information on the discovery and patenting of genes that influence the development of breast cancer by Myriad Genetics in Canada; Decision of the U.S. Supreme Court regarding the patentability of a single-celled bacterium in 1980; Bans on government funding for reproductive cloning; Provisions of the European Directive concerning biotechnological inventions.
ACCESSION #
12918680

 

Related Articles

  • Something Weird's Going Down in the Patent Office. PALOMBI, LUIGI // Issues;Dec2012, Issue 101, p4 

    The article discusses the court battles over the patenting of the genetic mutations to the BRCA1 and BRCA2 human genes linked t familial breast and ovarian cancers in the U.S. and Australia. It relates the amicus brief filed by doctor James Watson in the court battle over the validity of patents...

  • Malta provides loophole for breast-cancer screen. Check, Erika // Nature;10/24/2002, Vol. 419 Issue 6909, p767 

    Reports that Malta-based biotechnology firm Synergene claims to have found a loophole for breast-cancer screening held by Salt Lake City, Utah-based Myriad Genetics. Plans of Synergene to launch a diagnostic test for breast-cancer in January 2003; Amount to be charged by Synergene for the test;...

  • Supreme Court rules human genes cannot be patented. Wray, Charles; Hemphill, Nancy // Primary Care Optometry News;Jul2013, Vol. 18 Issue 7, p16 

    The article reports on the case involving patents held by Myriad Genetics for BRCA1/2 genes used to test if a woman has a risk for developing ovarian or breast cancer in which the U.S. Supreme Court ruled that genes and the information they encode are not eligible for patents.

  • The European BRCA patent oppositions and appeals: coloring inside the lines. Matthijs, Gert; Huys, Isabelle; Van Overwalle, Geertrui; Stoppa-Lyonnet, Dominique // Nature Biotechnology;Aug2013, Vol. 31 Issue 8, p704 

    The article discusses the patent related to issue of genes BRCA1 and BRCA2 used for diagnosis of familial breast cancer. It states that the patents on BRCA1 and BRCA2 genes by biotech company Myriad Genetics Inc. are subjected too much attention in the U.S. It further discusses the impact of...

  • WILL POLICY CONCERNS INVALIDATE MYRIAD GENETICS' GENE PATENTS? A BREAKDOWN OF VARIOUS JUDICIAL APPROACHE STOANALYZING PATENTABLE SUBJECT MATTER. OUTLAW, SARAH // Cumberland Law Review;2013, Vol. 43 Issue 3, p529 

    The article focuses on gene patents in the U.S. Topics discussed include gene patents in DNA sequencing for the treatment of breast cancer by molecular diagnostic company Myriad Genetics, living things being patentable following Diamond v. Chakraborty, the product of nature doctrine created by...

  • A victory for genes.  // Nature Medicine;Jul2013, Vol. 19 Issue 7, p792 

    The article deals with the U.S. Supreme Court's ruling on June 13, 2013 that human genes are unpatentable. The ruling invalidates claims by molecular diagnostics company Myriad Genetics in its patents on the breast cancer genes BRCA1 and BRCA2. The court used a section of the U.S. Code on patent...

  • Genetic patent singles out Jewish women. Abbott, Alison // Nature;7/7/2005, Vol. 436 Issue 7047, p12 

    Reports that the ruling of European Patent Office's (EPO) for breast cancer gene patent, BRCA2 gene filed by Myriad Genetics Inc. of Salt lake City, Utah, are under attack for allowing racial discrimination against Ashkenazi Jews. Revocation of the patent on the related BRCA1 gene filed by the...

  • THE PRACTICAL IMPLICATIONS OF ASSOCIATION OF MOLECULAR PATHOLOGY V. MYRIAD GENETICS, INC. AND BRCA1- & BRCA2-BASED HEREDITARY CANCER TEST PATENT LITIG. V. AMBRY GENETICS CORP. ON THE BIOTECHNOLOGY INDUSTRY. Berse, Samuel J. // Seton Hall Legislative Journal;2015, Vol. 39 Issue 2, p417 

    The article discusses practical implication of two U.S. court cases including Association for Molecular Pathology v. Myriad Genetics Inc. and BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig. v. Ambry Genetics Corp. on the biotechnology industry. Topics discussed include background of...

  • New Patent Rules for Genetic Material. Konski, Antoinette // BioPharm International;Aug2013, Vol. 26 Issue 8, p22 

    The article discusses the case of the Association for Molecular Pathology v. Myriad Genetics Inc. in which the U.S. Supreme Court ruled that isolated, naturally occurring genes and gene fragments are not patent-eligible. The biotechnology industry praised the ruling in which the court limited...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics